Navigation Links
Report Highlights Successful Strategies for Bringing FDC Products to Market
Date:1/5/2011

CHAPEL HILL, N.C., Jan. 5, 2011 /PRNewswire/ -- The pharmaceutical industry's steep patent cliff and relatively lackluster pipeline is pushing strategy and development executives to uncover opportunities for sustainable growth in 2011. One opportunity lies in combination therapies with branded products to extend patent life. For pharma companies, fixed dose combination (FDC) products can extend a therapeutic advantage and become part of lifecycle management. For the patient, FDC products can address unmet medical needs and reduce pill burdens.

While FDC products can have clinical and commercial advantages, they also can be challenging to bring to market. A new Best Practices, LLC report found it takes between five and eight years and an average of $80 million to bring a FDC product to market. One of the keys to successfully commercializing a FDC therapy is to create a differentiated product with a therapeutic benefit, according to the research project.

Indeed, critical product-shaping strategies such as positioning and value were tactics that veteran FDC leaders identified as most valuable for a successful launch of a FDC product, according to "Fixed Dose Combination Products: Successful Strategies for Developing and Bringing FDC Products to Market." As one R&D veteran noted in the report, "Bring some value to the payers. If a payer looks at it and there's not really any kind of clinical differentiation, whether it's better efficacy, speed of onset, better response, or better remission, the payers tell us very, very clearly that they're not interested."

Some of the issues addressed in this research include:

  • Chief reason for pursuing FDC development
  • Measures used to evaluate success
  • Years from decision to develop through launch
  • Cost of FDC product development Approximate
  • Difficulty areas for bringing FDC product to market
  • Reasons for partnering with another company to develop FDC product
  • Time lapsed from initial contact to signed contractual agreement with partner
  • U.S. filing routes used
  • EU filing routes used
  • Months from filing to approval
  • Pre-launch marketing challenges
  • Strategies, tactics, practices to help accelerate or impede launch progress
  • Lessons learned from executives
  • Metrics for effectively communicating business value

The full 55-page report contains more than 150 benchmark metrics, providing executives with the tools, tactics and techniques to help organizations successfully develop and commercialize fixed dose combination products. Review a complimentary summary of the study at http://www3.best-in-class.com/rr1037.htm. The summary includes selected best practices drawn from extensive primary research with 51 representatives from 34 leading companies, including eight of the Top 20 pharma companies. 

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.  For more information about the company, go to www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Michigan Pre-Seed Capital Fund Reports Investments Totaling $2.5 Million in 2010
2. Elektas MOSAIQ Oncology Information System Named Category Leader in 2010 Top 20 Best in KLAS Awards Report
3. Reportlinker Adds Cosmetic Surgery Products
4. Complaints and Concerns about Medicare Competitive Bidding for Home Medical Equipment Can Be Reported Via a Toll-Free Number and Website
5. Reportlinker Adds Regenerative Medicine Markets
6. Reportlinker Adds Womens Health Diagnostic Testing
7. Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry
8. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
9. Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia
10. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
11. Reportlinker Adds Mammography World Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... the only authorized OSHA Training Institute Education Center headquartered in Northern California, has ... workers from extreme heat at their worksites. Employers with workers exposed to ...
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):